<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538391</url>
  </required_header>
  <id_info>
    <org_study_id>12/2019OBSGN38</org_study_id>
    <nct_id>NCT04538391</nct_id>
  </id_info>
  <brief_title>Intra Incisional Infiltration of Bupivacaine Versus Meloxicam on Post Cesarean Section Pain Relief</brief_title>
  <official_title>Bupivacaine Versus Meloxicam Infiltration on Post Cesarean Section Pain Relief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation: compare the effect of local infiltration of incision site with bupivacaine and&#xD;
      local infiltration with meloxicam in women undergoing cesarean sections on postoperative pain&#xD;
      relief and analgesic requirement.&#xD;
&#xD;
      Condition: post cesarean sections analgesia intervention: infiltration of incision&#xD;
      bupivacaine versus meloxicam Phase: Not applicable&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      study type: randomized clinical trial actual enrollment: 119 allocation: Random intervention&#xD;
      model: three groups assignment masking: open lebal primary purpose: pain relief after&#xD;
      Cesarean section actual study start: March 3, 2019 Primary Completion: March 5, 2020 actual&#xD;
      study completion date: May 9, 2020&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2019</start_date>
  <completion_date type="Actual">May 9, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A (bupivacaine group): included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.&#xD;
Group B (meloxicam group): included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.&#xD;
Group C (placebo group): included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Each woman received a disposable syringe containing a medication corresponding to her order of participation in the trial. Packing. Sealing and numbering were performed by health care provider who did not actively share in the process of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Assessment of pain scores after Cesarean section</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative analgesic requirements</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Assessment of Postoperative analgesic requirements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of first dose of analgesia</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Determination of time of first dose of analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative fever</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Assessment of Postoperative fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>onset of mobilization</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Assessment of onset of mobilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of medications</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Assessment of side effects of medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment by visual analogue scale</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>Post-operative pain assessment was done using a 10-point visual analogue scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Cesarean Section Pain</condition>
  <arm_group>
    <arm_group_label>bupivacaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meloxicam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>local ifiltration Bupivacaine, Meloxican and placebo</intervention_name>
    <description>no other intervention done</description>
    <arm_group_label>bupivacaine group</arm_group_label>
    <arm_group_label>meloxicam group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21-40 years&#xD;
&#xD;
          -  Elective C.S at term&#xD;
&#xD;
          -  Patient having no medical disorders&#xD;
&#xD;
          -  Patient with no obstetrical complications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extreme of reproductive age&#xD;
&#xD;
          -  allergy to local anesthetic infiltration agent&#xD;
&#xD;
          -  any medical disorders or obstetrical complications as ante partum hemorrhag,&#xD;
             pre-eclampsia&#xD;
&#xD;
          -  refusal to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed E Anter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menoufia University hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Menoufia University hospital</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <state>Menoufia</state>
        <zip>11111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 29, 2020</last_update_submitted>
  <last_update_submitted_qc>August 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia Obstetrics and Gynecology Group</investigator_affiliation>
    <investigator_full_name>Mohamed Elsibai Anter</investigator_full_name>
    <investigator_title>Lecturer of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>through the E-maill address</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

